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Purpose of Review:  Breathlessness and chronic inflammation both span a wide range of 
disease contexts and hold prognostic significance. The possibility of a causal relationship 
between the two has been hypothesised. The aims of this article are 1) to review the 
intersections between breathlessness and inflammation in the literature, 2) to describe 
potential mechanisms connecting the two phenomena, and 3) to discuss the potential clinical 
implications of a causal relationship. 
Recent findings: There is a very limited literature exploring the relationship between 
systemic inflammation and breathlessness in COPD, heart failure and cancer. One large 
study in cancer patients is suggestive of a weak association between self-reported 
breathlessness and inflammation. Studies exploring the relationship between inflammation 
and MRC Dyspnoea grade have produced inconsistent findings.  Though a causal 
relationship has not yet been demonstrated, this relationship might be mediated through the 
effects of both inflammation and breathlessness on the skeletal muscle and stress hormone 
systems. 
Summary: There is much progress to be made in this area. Interventional studies, 
evaluating the impact of anti-inflammatory interventions on breathlessness, are needed to 
help determine whether a causal relationship exists. If proven, this relationship might have 
important implications for both the treatment and impact of breathlessness. 
Breathlessness and Inflammation: 
relationship and implications
Introduction
Chronic breathlessness is a distressing symptom, of growing significance, which affects 
millions of people throughout the world (1). Its genesis is multifactorial, resulting from the 
interaction of physiological, psychological, social and environmental factors (2). Though it is 
highly prevalent in cardiorespiratory disease, such as COPD and heart failure (3), the 
experience of breathlessness extends far beyond this context. It is a prominent symptom in 
panic disorder (4), in the frail elderly (5), and in the last weeks of life (6). Severity of 
breathlessness has been shown to predict mortality independent of underlying lung function 
in both COPD (7) and pulmonary fibrosis (8). It also predicts 10-year mortality in older adults 
independent of age, gender and underlying disease (9). These facts suggest that the 
symptom of breathlessness has an origin and impact beyond that of the lungs. Indeed, there 
is growing recognition of breathlessness as a disorder of the brain, where input from multiple 
peripheral systems is centrally co-ordinated, rather than the cardiorespiratory system (10).
Chronic inflammation is a process that has the potential to explain the presence of 
breathlessness across a range of contexts, as well the independent relationship between 
breathlessness and prognosis. The term ‘inflammation’ may be defined as ‘a complex 
biological response of vascular tissues to harmful stimuli’ (11). It results in the release of a 
heterogeneous group of polypeptides or gylcoproteins, termed ‘cytokines’, which influence 
cell growth, differentiation and activation, and which facilitate communication between both 
cells and tissues (12). In the clinical setting, this response is characterised by raised levels of 
plasma biomarkers including cytokines [e.g. interleukin-6 (IL-6) and tumour necrosis factor-α 
(TNF-α)], cytokine antagonists, acute-phase proteins [e.g. C-reactive protein (CRP)], and 
immune cells [e.g. neutrophils and natural killer (NK) cells] (13). 
In the short-term, the inflammatory response is protective and beneficial. In the long-term, 
however, chronic activation of this state may result in significant tissue damage.  
Accordingly, chronic systemic inflammation has been associated with a wide range of 
diseases including COPD (13-18), heart failure (19, 20), metabolic syndrome (21), and 
autoimmune disorders such as multiple sclerosis and SLE (22). It has also been linked to the 
development of psychiatric disorders such as depression and bipolar disorder (23). 
Furthermore, there is evidence associating it with a range of cancer symptoms including pain 
(24), anorexia-cachexia syndrome (25, 26), depression (27, 28) and fatigue (29). Indeed, it 
has been proposed that chronic inflammation may underlie the commonly observed 
clustering of these symptoms within individual cancer patients, a theory supported by the 
animal model of cytokine-induced sickness behaviour (30-32).
To date, the relationship between breathlessness and inflammation has not been explicitly 
investigated. There are some clues in the literature that might suggest a relationship, 
however. The aim of this article is to review the intersections between breathlessness and 
inflammation in the literature and to describe postulated mechanisms which may connect the 
two phenomena. 
Evidence linking breathlessness and inflammation
Chronic inflammation has been studied extensively in the context of COPD, heart failure and 
cancer. Though the relationship between breathlessness and chronic inflammation has not 
been of primary interest within such studies, the measurement of breathlessness-related 
constructs within some of these studies provides insight into this relationship.  
A small number of studies have investigated inflammation in relation to disability due to 
breathlessness, as measured using the MRC Dyspnoea grading system, in patients with 
COPD. Whilst Pinto-Plata et al. (15) (n=88) did not identify a significant association between 
MRC Dyspnoea grade and CRP, Garrod et al. (33) (n=43) demonstrated that those with an 
MRC Dyspnoea grade of 5 had significantly higher inflammatory markers (CRP and IL-6) 
than those with an MRC Dyspnoea grade of 1-2. More recently, in a large cohort study of 
1775 COPD patients (ECLIPSE), the subgroup with persistent inflammation at one year of 
follow-up (16%) were observed to have a higher mean MRC Dyspnoea grade at 
baseline(34). This variable was not found to be an independent predictor of inflammation in a 
logistic regression model, however. 
There has been very limited study of systemic inflammation in relation to the sensory or 
perceptual experience of breathlessness. The findings from one large European study, 
which included 1446 patients with advanced cancer, suggest  that inflammation may be as 
relevant to breathlessness as it is to the other self-reported cancer symptoms (31). In this 
cross-sectional analysis, a wide range of symptoms were measured using the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire- Core 
Questionnaire (EORTC QLQ- C30), and CRP levels were found to correlate significantly with 
dyspnoea, as well as pain, fatigue, anorexia, and cognitive dysfunction. Interestingly, the 
correlation with CRP was low for all symptoms, with the correlation between CRP and 
dyspnoea (r=0.150) being similar to that for CRP and pain (r=0.154). It is noteworthy that 
these low correlations were considered to be clinically significant by the authors due to the 
multiple factors affecting both inflammation and symptoms in this patient sample. 
Systemic inflammation has also been explored in relation to the New York Heart Association 
(NYHA) grading system in patients with heart failure and in relation to exercise tolerance in 
COPD. In a cross-sectional study involving 66 patients with heart failure, Nozaki et al. (20) 
identified that soluble TNF-α receptor levels increased significantly as NYHA grade 
increased. Furthermore, Dixon et al. (35) demonstrated a significant positive association 
between NYHA grade and levels of both TNF-β and IL-10 in a sample of 30 heart failure 
patients. In COPD, exercise tolerance has been found to be significantly associated with 
markers of inflammation in a number of cross-sectional studies. Yende et al. (36) (n=187) 
found that IL-6 levels predicted exercise tolerance, independent of quadriceps strength. 
Pinto-Plata et al. (15) (n=88) identified a significant inverse association between 6-minute 
walk distance and CRP level, independent of age and lung function. Similarly, Broekhuizen 
et al.(37) (n=102) demonstrated that exercise capacity and 6-minute walk distance were 
significantly lower in those with a raised CRP in comparison to those with a normal CRP, 
despite a similar mean FEV1 for both groups. 
Finally, there is some evidence in the literature to suggest a relationship between systemic 
inflammation and quality of life in COPD, a construct to which breathlessness contributes. 
Broekhuizein et al. (37) (n=102) found that patients with a raised CRP had a significantly 
higher score on the symptom domain of the St. George’s Respiratory Questionnaire 
(SGRQ). Similarly, Garrod et al. (33) (n=43) demonstrated a moderate positive correlation 
between CRP level and total SGRQ score (r=0.43, p<0.01). This relationship has recently 
been confirmed in a large longitudinal study (ECLIPSE), where SGRQ was found to be an 
independent predictor of systemic inflammation at one-year follow-up (34). 
Potential mechanisms linking breathlessness and inflammation 
Whilst some of the evidence outlined above points to a possible association between 
breathlessness and inflammation, none of the evidence is sufficient to prove a causal 
relationship. There is compelling evidence in the literature of mechanisms which might 
causally link breathlessness to inflammation, however. Two possible mechanisms appear to 
link breathlessness and inflammation in a bidirectional manner, suggesting particular 
relevance. These mechanisms arise through the effects of breathlessness and inflammation 
on 1) the skeletal muscle system, and 2) the stress hormone system (see Figure 1). 
The skeletal muscle system
One hypothesis linking breathlessness and systemic inflammation is that systemic 
inflammation contributes to breathlessness through its effects on skeletal muscle. This 
hypothesis is illustrated in Figure 1. 
Lower limb muscle dysfunction is characterised by muscle atrophy, a shift from type I to type 
II fibres, mitochondrial dysfunction, reduced oxidative capacity, and muscle weakness 
(38).There is growing evidence in the literature supporting the independent contribution of 
this condition to the genesis of breathlessness. Quadriceps muscle strength has been shown 
to be inversely associated with exertional breathlessness both in patients with 
cardiorespiratory disease (39) and in older adults (5). In addition, physiological studies in 
COPD patients suggest that lower limb muscle dysfunction results in early development of 
lactic acidosis during exercise, with a consequent increase in neural respiratory drive, and 
thus breathlessness (40, 41). There is also evidence that ventilatory drive is increased as a 
result of direct feedback to the CNS from grade III/IV sensory afferents in lower limb muscle 
as they respond to the local release of anaerobic metabolites during exercise (42).
Systemic inflammation is known to contribute to muscle wasting in a range of conditions 
including  sepsis, cancer, and COPD (43-45). Several cytokines, particularly TNF-α, are 
known to upregulate expression of NF-κB in muscle tissue, a key transcription factor which 
regulates the ubiquitin-proteasome pathway, a major effector of proteolysis (44). In animal 
studies, IL-6 has been shown to induce proteolysis pathways  (46) and to inhibit the 
secretion and activity of insulin-like growth factor I (IGF-1) (47). Furthermore, anti-IL-6 
receptor antibodies have been shown to reverse muscle wasting in IL-6 transgenic mice 
(46). 
In the context of breathlessness, systemic inflammation may arise in response to the 
underlying disease or in response to breathlessness-induced inactivity. Inactivity is 
considered to be a major contributor to skeletal muscle dysfunction in the context of 
breathlessness, as evidenced by longitudinal studies in COPD patients (38, 48). Though 
disuse of muscle is itself a direct activator of the ubiquitin-proteasome pathway (44), 
inactivity might also cause muscle wasting by activating the systemic inflammatory 
response. In support of this hypothesis, several population cohort studies have shown 
evidence of an inverse relationship between levels of CRP and physical activity (49, 50). 
Furthermore, a number of interventional studies, conducted in diverse health populations, 
have shown a reduction in inflammatory markers after exercise-training, suggesting a causal 
relationship between physical activity and inflammation, which is currently not fully 
understood (49). 
Thus, breathlessness may contribute to systemic inflammation through inactivity and 
systemic inflammation (either due to inactivity or the underlying disease) may, in turn, 
contribute to breathlessness through its effects on muscle catabolism.  
The stress hormone system
A second hypothesis linking breathlessness and inflammation is that breathlessness causes 
systemic inflammation through the effects of breathlessness-related stress on the 
hypothalamic-pituitary-adrenal (HPA) axis (51). This hypothesis is illustrated in Figure 1. 
The relationship between breathlessness and emotion is well-established in the literature. 
Qualitative studies of the experience of breathlessness suggest a bidirectional relationship 
between breathlessness and anxiety, where anxiety is both a response to and a trigger for 
breathlessness (52). The perception of breathlessness is known to have both sensory and 
affective dimensions (53, 54), and negative affective states have been shown in laboratory 
studies to modulate the affective dimension (55). Furthermore, functional imaging studies 
have shown that breathlessness is processed in the insular cortex, the amygdala and the 
anterior cingulate cortex (56, 57), areas of the brain involved in emotion and behaviour 
regulation in response to stressful physical and psychological stimuli (51, 58) (see Figure 2). 
These observations all suggest that the stress hormone system may be engaged by the 
experience of breathlessness. 
The hypothalamic-pituitary-adrenal (HPA) axis is a key component of the stress hormone 
system. This axis regulates the production of glucocorticoids, such as cortisol, in response to 
stress, through a negative feedback loop (see Figure 2). In the context of repeated or 
prolonged exposure to stressful triggers (as might occur in chronic breathlessness), this 
regulatory system becomes dysregulated, which may manifest as loss of diurnal variation in 
cortisol secretion, hypercortisolism or hypocortisolism (59, 60). 
There is ample evidence in the literature of close interaction between the HPA axis and the 
systemic inflammatory response, with inflammation being both a cause and a consequence 
of HPA axis dysregulation. Cytokines, such as IL-1, IL6, TNF-α, and INF-α, have been 
shown to activate the HPA axis and downregulate glucocorticoid receptors in several studies 
(23), resulting in decreased negative feedback and excessive stimulation of the HPA axis in 
chronic inflammatory states. Importantly, this cytokine-induced HPA activity has been shown 
to be requisite for cytokine-induced muscle-atrophy (61). Dysfunctional HPA axis activity 
itself has been shown to result in increased levels of systemic inflammation both in the 
context of hypocortisolism and hypercortisolism, the former due to loss of cortisol-induced 
anti-inflammatory effects and the latter due to glucocorticoid resistance (62). Consistent with 
this, HPA axis dysregulation has been identified in association with several auto-immune, 
inflammatory and metabolic disorders (62). 
Thus, breathlessness-induced stress may result in HPA axis dysregulation, resulting in 
systemic inflammation, which, in turn, may contribute to breathlessness through effects on 
the skeletal muscle system. 
Future research and clinical implications
The hypotheses presented in this article suggest that systemic inflammation may contribute 
to and be a consequence of chronic breathlessness. It is now necessary to test these 
hypotheses and prove this relationship. 
A major barrier to knowledge of this relationship to date has been the lack of measurement 
of breathlessness, alongside markers of inflammation, in clinical studies. Though many 
studies have explored the relationship between inflammation and breathlessness-related 
constructs, no studies have undertaken detailed assessments of breathlessness alongside 
markers of inflammation, taking into account both the sensory and affective dimensions of 
breathlessness, as well as its impact on function. Inadequate measurement of 
breathlessness is likely to result in false negative findings in association studies.
With robust measures of breathlessness on board, it would be useful to conduct a 
longitudinal study to assess the temporal relationship between breathlessness, inflammation, 
psychological stress, HPA axis dysfunction and muscle wasting. This would facilitate the 
design and interpretation of later interventional studies conducted to test the specific 
mechanistic hypotheses. An obvious interventional study would be the investigation of the 
effect of an anti-inflammatory intervention on breathlessness, as well as its effects on 
skeletal muscle and HPA axis function. This design would allow both the causal relationship 
and its mediators to be examined.  
If systemic inflammation were proven to contribute to the genesis of breathlessness, this 
would open the door to a wide range of potential anti-inflammatory therapies in the treatment 
of breathlessness. Possible candidate agents might include cytokine inhibitors, NSAIDs, 
eicosapentanoic fatty acid supplements, and exercise. Randomised controlled trial 
evaluation of each of these agents would be necessary, with breathlessness as the primary 
endpoint and skeletal muscle function, inflammation and HPA axis function as intermediate 
or biomarker endpoints. Interventions which target the hypothesised mediators of the 
breathlessness-inflammation relationship might, alternatively, be more effective than 
targeting inflammation directly, as these agents would have a direct effect on both 
breathlessness and inflammation, as well as an indirect effect on breathlessness through 
inflammation. Such agents include exercise (targeting skeletal muscle) and psychological 
therapies (targeting stress and the HPA axis). 
If systemic inflammation were proven to be a consequence of breathlessness, this might 
explain the currently unexplained association between breathlessness severity and mortality 
across a range of diagnoses including COPD (7), pulmonary fibrosis (8), cancer(63) and the 
elderly (9). It might also explain the survival benefit associated with breathlessness 
management in a recent RCT evaluation of a multi-disciplinary breathlessness service (64). 
Given the effects of systemic inflammation on mood and skeletal muscle, breathlessness-
induced systemic inflammation might also contribute to the depression and disability 
commonly seen in association with breathlessness. Thus, treatment of breathlessness or 
associated systemic inflammation might confer benefits beyond relief of the symptom itself. 
Conclusion
The relationship between systemic inflammation and breathlessness is virtually unexplored 
in the literature.  This relationship is certainly worthy of investigation given the observed 
associations between inflammatory markers and breathlessness-related constructs in the 
literature, the availability of plausible mechanistic hypotheses linking the two phenomena, 
and the potential clinical implications that a proven causal relationship might confer. Whilst it 
is exciting to contemplate these possible links, there is much work to done in this field, and it 
is now necessary to move from theoretical postulation to investigation.
Key points
• The relationship between systemic inflammation and chronic breathlessness has been 
explored, as a secondary objective, in a small number of studies
• Some studies have reported a significant association between markers of inflammation 
and constructs relating to breathlessness, including self-reported breathlessness 
intensity, disability due to breathlessness, quality of life, and exercise-tolerance. Causal 
inferences cannot be made from these studies, however. 
• A causal relationship between breathlessness and systemic inflammation, if proven, 
might be mediated through the effects of both phenomena on skeletal muscle function 
and stress homorne regulation. 
• The relationship between breathlessness and inflammation needs significant further 
investigation, which will necessitate the conduct of interventional studies. 
Figure 1: Hypothesised relationship between breathlessness and systemic 
inflammation. 
A bidirectional relationship exists between 1) breathlessness and skeletal muscle 
dysfunction, and 2) breathlessness and stress. Systemic inflammation has a bidirectional 
relationship with both skeletal muscle dysfunction and stress and may indirectly influence 
breathlessness through these relationships. Abbreviations: HPA, hypothalamic-pituitary-
adrenal axis. 
Figure 2. Schematic diagram of the HPA axis, showing its regulation by the amydala, 
midbrain, prefrontal cortex and hippocampus, and illustrating the negative feedback 
regulation of cortisol via glucocorticoid receptors.  
Activation and inhibition are indicated by the symbols ‘+ve’ and ‘-ve’, respectively.  
Abbreviations: PVN, paraventricular nucleus; CRH, corticotrophin releasing hormone; GR, 
glucoreceptor; MR, mineralocorticoid receptor. 
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